Drug intelligence / Profile preview

sildenafil + apixaban

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of two distinct medications: sildenafil (a phosphodiesterase type 5 (PDE5) inhibitor primarily used for erectile dysfunction and pulmonary arterial hypertension) and apixaban (a direct oral anticoagulant that inhibits Factor Xa, used to prevent and treat blood clots in conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism). According to the search results, there is a potential drug-drug interaction between these medications. An in vitro study found that sildenafil strongly inhibited apixaban efflux by P-glycoprotein (P-gp), suggesting that sildenafil may increase apixaban levels in the body. The serum concentration of sildenafil can also potentially be increased when combined with apixaban. This combination requires caution as PDE5 inhibitors like sildenafil may slightly raise the chances of bleeding, which is particularly concerning when taken with blood thinners like apixaban. While research suggests the bleeding risk may not be significant, healthcare professionals should make the final decision on whether it's appropriate to take these medications together. For patients taking both medications, it's important to monitor for any signs of bleeding such as nosebleeds, bleeding gums, or bloody stools, and report these immediately to a healthcare professional.

02

Targets

ABCB1 (P-glycoprotein)PDE5 (Phosphodiesterase 5A)F10 (Factor Xa)

Beyond the preview

Go deeper on sildenafil + apixaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sildenafil + apixaban.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call